Search This Blog

Monday, January 27, 2020

Applied Genetics +3.8% as Roth starts at Buy

Applied Genetic Technologies (NASDAQ:AGTC) is up 3.8% postmarket following an initiation at Buy by Roth Capital.
Roth’s Jallah Zegbeh sees 218% upside, setting a price target of $25; shares had closed up 6.2% against today’s down market, to $7.86.
https://seekingalpha.com/news/3534971-applied-geneticsplus-3_8-roth-starts-buy

FDA OKs Trijardy for patients with type 2 diabetes, Eli Lilly says

Eli Lilly (NYSE:LLY) says the Food and Drug Administration approved its Trijardy XR tablet to help lower blood sugar in adults with type 2 diabetes.
Lilly says Trijardy combines three medicines – Jardiance (empagliflozin), Tradjenta (linagliptin) and metformin hydrochloride extended release – in one pill, which will be a once-a-day medication.
The FDA approval was based on two randomized open-label trials that assessed the bioequivalence of empagliflozin, linagliptin and metformin hydrochloride extended release fixed-dose combination tablets and their individual components in healthy adults.
https://seekingalpha.com/news/3534972-fda-oks-trijardy-for-patients-type-2-diabetes-eli-lilly-says

China’s coronavirus has not mutated in the US, says CDC

US health authorities said Monday they have sequenced the genome of the first two cases of the Chinese coronavirus reported in the country and confirmed the virus has not mutated since leaving China.
Nancy Messonnier, head of respiratory diseases at the Centers for Disease Control and Prevention (CDC) said she was planning imminent changes on measures to control and track the , beyond the current restrictions just on travelers arriving from the city Wuhan, which is at the epicenter of the outbreak.
“Right now, and based on CDC’s analysis of the available data, it doesn’t look like the [] has mutated,” she said in a telephone news conference.
“All the sequences we’ve extracted are similar to the one that China initially posted a couple of weeks ago,” she said.
All passengers arriving from Wuhan are currently subject to testing in five US airports, but since China has suspended all flights out of the stricken city, there are fewer and fewer travelers from there arriving in the US.
The virus has also reached other Chinese provinces and China has announced that people who are infected can spread the disease before they show any symptoms of fever or respiratory difficulties.
That has rendered redundant the current measures to contain the virus in the US.
“I expect that in the coming days, our travel recommendations will change,” said Messonnier. “I expect there will be a decision, and an announcement about that within the next day.”
Despite that, the CDC still estimates the risk from the virus to Americans to be low.
“At this time in the US, this virus is not spreading in the community,” Messonnier said.
There have been five confirmed cases in the country and 110 patients have either been under observation or are currently being tested in 26 states. Aside from the five who so far tested positive, 32 have tested negative.
It takes around a day to receive the test results from suspected cases because have to be sent to the CDC headquarters in Atlanta, Georgia.
https://medicalxpress.com/news/2020-01-china-coronavirus-mutated-cdc.html

Study finds inconsistencies in a broadly used autism test

Rutgers researchers have found that a test widely used to diagnose whether children have autism is less reliable than previously assumed.
The study is published in the journal Neural Computation.
The standardized , known as the Autism Diagnostic Observation Schedule (ADOS), assesses , and play for children who may have autism or other developmental disorders.
The researchers digitized the test by attaching wearable technology, like an Apple Watch, to two clinicians and 52 children who came in four times and took two different versions of the test.
When researchers looked at the scores of the entire cohort, they found they did not distribute normally—which could mean a chance of false positives inflating the prevalence of autism, among other implications.
The results showed that switching clinicians may change a child’s scores and consequently influences the diagnosis. The researchers found similar results when they analyzed open-access data of 1,324 people ages five to 65, said Elizabeth Torres, associate professor of psychology in Rutgers’ School of Arts and Sciences, and director of the New Jersey Autism Center of Excellence.
“The ADOS test informs and steers much of the science of autism, and it has done great work thus far,” said Torres, whose expertise has brought emerging computer science technology to autism. “However, social interactions are much too complex and fast to be captured by the , particularly when the grader is biased to look for specific signs and to expect specific behaviors.”
The researchers suggest combining clinical observations with data from wearable biosensors, such as smartwatches, smartphones and other off-the-shelf technology.
By doing so, they argue, researchers may make less invasive, lower the rate of false positives by using empirically derived statistics rather than assumed models, shorten the time to diagnosis, and make diagnoses more reliable, and more objective for all clinicians.
Torres said researchers should aim for tests that capture the accelerated rate of change of neurodevelopment to help develop treatments that slow down the aging of the nervous system.
“Autism affects one out of 34 children in New Jersey,” she said. “Reliance on observational tests that do not tackle the neurological conditions of the child from an early age could be dangerous. Clinical tests like the ADOS score a child based on expected aspects of behaviors. These data are useful, but subtle, spontaneous aspects of natural behaviors, which are more variable and less predictable, remain hidden. These hidden aspects of behavior may hold important keys for personalized treatments, like protecting nerve cells against damage, or impairment, which could delay or altogether stop progression.”

Explore further
One-fourth of children with autism are undiagnosed

More information: Elizabeth B. Torres et al. Hidden Aspects of the Research ADOS Are Bound to Affect Autism Science, Neural Computation (2020). DOI: 10.1162/neco_a_01263

Pfizer Q4 2019 Earnings Preview

Pfizer (NYSE:PFE) is scheduled to announce Q4 earnings results on Tuesday, January 28th, before market open.
The consensus EPS Estimate is $0.54 (-15.6% Y/Y) and the consensus Revenue Estimate is $12.73B (-8.9% Y/Y).
Over the last 2 years, PFE has beaten EPS estimates 100% of the time and has beaten revenue estimates 63% of the time.
Over the last 3 months, EPS estimates have seen 7 upward revisions and 3 downward. Revenue estimates have seen 5 upward revisions and 2 downward.
https://seekingalpha.com/news/3534764-pfizer-q4-2019-earnings-preview

Fed Adds Nearly $50 Billion to Markets, but Overall Temporary Liquidity Declines

The Federal Reserve Bank of New York executed a $49.6 billion overnight liquidity operation Monday that moderately reduced the overall amount of temporary money the central bank has injected into short-term financial markets.
The Fed’s repurchase agreement operation, or repo, added nearly $50 billion, as dealers submitted to the Fed $26.5 billion in Treasurys and $23.1 billion in mortgages. Because of the expiration of past interventions, the overall amount of liquidity added by the Fed Monday declined $5.7 billion to $181.6 billion.
Fed repo interventions take in Treasurys, agency and mortgage bonds from eligible banks in what is effectively a short-term loan of central-bank cash, collateralized by the securities. The banks tapping this cash — they are called primary dealers — are limited in the amount of liquidity they can take in exchange for their securities, and they pay interest to the central bank to get the funds.
The amount of outstanding Fed repos has fallen considerably since the turn of the year. Then, the Fed, concerned that a variety of factors would cause money-market lenders to refrain from their normal lending, in turn pushing up rates, flooded the market with money to ensure stability. Based on the lack of movement in rates, it worked.
The year-end operations “are unwinding pretty smoothly,” said Scott Skyrm, executive vice president in fixed income and repo at Curvature Securities. The average amount of outstanding repos during the first two weeks of the year stood at $229 billion, and over the last week it has averaged $150 billion, with no negative impact on how short-term rates are performing, he said.
The Fed also added permanent liquidity to the financial system via another round of Treasury bill buying Monday. It purchased $7.5 billion in bills, which have maturities of less than a year, in an operation that saw primary dealers submit $25.5 billion to the central bank.
Fed money-market interventions aim to keep the federal-funds rate within the central bank’s 1.5%-to-1.75% target range and limit the volatility of other money-market rates. The Fed controls the fed-funds rate to influence the overall cost of borrowing in the U.S. economy as part of its efforts to achieve the job and inflation goals set for it by Congress.
The Fed restarted its repo operations in September after a decadelong break in the wake of unexpected money-market volatility. Demand for Fed money has waxed and waned, and by and large the Fed has restored calm to markets and kept short-term rates where it wants.
The Fed has used repo operations for decades to influence short-term rate settings.
The Fed’s short-term repo operations are scheduled to run through the middle of February. They will likely go on for a number of months longer than the end-of-January stop the Fed has originally planned for, however. Treasury bill buying was supposed to build up enough permanent liquidity in short-term markets to end the need for repos, but there is now less certainty about what has been causing frictions, and how to fix it.
The Fed’s money-market plans and their effect on the central bank’s balance sheet are likely to be a focus of this week’s rate-setting Federal Open Market Committee meeting, which will be held over Tuesday and Wednesday, followed by a press conference by Fed Chairman Jerome Powell.
There are worries in markets, shared to some degree by Dallas Fed leader Robert Kaplan, that the Fed’s market interventions are driving up financial-market risk taking, and that the longer the buying goes on, the more problematic this might become. There are also concerns that due to seasonal factors, there may even be a shortage of Treasury bills for the Fed to buy, which might force them into longer-dated securities, which may in turn bolster the idea Fed money-market interventions are stimulus, and not technical, as officials have claimed.
The central bank said last week that as of Wednesday its balance sheet stood at $4.15 trillion, down $29.9 billion from the week before. Fed holdings were at $3.8 trillion in September and peak Fed holdings were $4.5 trillion in the wake of the financial crisis. About $186.1 billion in repos were outstanding on Wednesday.
https://www.marketscreener.com/news/Fed-Adds-Nearly-50-Billion-to-Markets-but-Overall-Temporary-Liquidity-Declines-Update–29897797/

Could a Common Diuretic Med Help Ease Autism Symptoms?

A prescription drug that’s long been used to treat the buildup of fluid in the body might do double duty as a means of easing autism symptoms in young children, new research shows.
If replicated in future trials, the drug treatment might be a breakthrough, since current treatments for autism in preschool kids are mainly behavioral — therapies such as using play and activities with parents to improve a child’s language, social and thinking skills.
The drug bumetanide is currently used to help reduce fluid-linked swelling that comes with heart failure or kidney disease.
But bumetanide may improve autism symptoms by affecting two chemical “messengers” that help nerve cells in the brain communicate. The drug appears to lower the ratio of one key brain chemical called GABA, to another chemical called glutamate, explained a team from the University of Cambridge and several institutions in Taiwan and China.
It’s this mechanism that appears to help ease autism symptoms.
“This is the first demonstration that bumetanide improves brain function and reduces symptoms by reducing the amount of the brain chemical GABA,” said researcher Ching-Po Lin, of National Yang-Ming University in Taipei, Taiwan.
Speaking in a Cambridge news release, he said, “Understanding this mechanism is a major step towards developing new and more effective drug treatments.”
Study co-author Barbara Sahakian, from Cambridge’s department of psychiatry, agreed.
“This study is important and exciting, because it means that there is a drug that can improve social learning and reduce [autism] symptoms during the time when the brains of these children are still developing,” she said in the release.
“We know that GABA and glutamate are key chemicals in the brain for plasticity and learning and so these children should have an opportunity for better quality of life and well-being,” Sahakian said.
According to the researchers, prior studies in rats and small clinical trials involving children had suggested that bumetanide might help reduce symptoms of autism.
The new study was still relatively small — just 83 children with autism, ranging between 3 to 6 years of age. The children were divided: One group of 42 received 0.5 milligrams of bumetanide twice a day for three months, while a “control” group of 41 children received no treatment.
Along with reducing autism symptoms, bumetanide appeared to cause no significant side effects, according to the study published Jan. 26 in Translational Psychiatry.
Any medicine that might alleviate autism symptoms would be very welcome, because behavioral treatments are not always accessible, particularly in developing countries, the research team noted.
“I have many children with autism spectrum disorder under my care, but as psychological treatment resources are not available in many places, we are unable to offer them treatment. An effective and safe treatment will be very good news for them,” study clinical leader Dr. Fei Li, of Jiao Tong University School of Medicine in Shanghai, said in the release.
Dr. Andrew Adesman directs developmental and behavioral pediatrics at Cohen Children’s Medical Center of New York in New Hyde Park. He wasn’t involved in the new study, but was cautiously optimistic about the results.
Future trials will reveal how useful bumetanide might be against autism.
“Several methodologically rigorous, double-blind, placebo-controlled studies are now underway,” Adesman noted, “and we should know much more in a year or two as to whether bumetanide is indeed safe and effective.”
The current trial did have one key shortcoming, he said.
“Because this study lacked a placebo control group, it is hard to know if all of the clinical improvements reported were due to the bumetanide treatment itself or to placebo effects,” Adesman said. But he said certain brain scan evidence presented in the study does suggest a real and beneficial effect.
Adesman added that parents should probably not demand the drug for their kids just yet, however.
“I think families should wait until we know a little more about its potential benefits and side effects,” he said. “We need a methodologically rigorous, well-designed clinical trial to better assess the clinical benefits of bumetanide.”
More information
The Autism Society has more on autism.
SOURCES: AndrewAdesman, M.D.,chief, Developmental and Behavioral Pediatrics, Cohen Children’s Medical Center of New York, New Hyde Park, N.Y.; University of Cambridge, news release, Jan. 26, 2020
https://consumer.healthday.com/cognitive-health-information-26/autism-news-51/could-a-common-diuretic-med-help-ease-autism-symptoms-754294.html